Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin

The Journal of Clinical Endocrinology and Metabolism
Akihiro YoshidaHirohito Sone

Abstract

Although calorie loss from increased urinary glucose excretion continues after long-term treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2is), the mechanisms of the attenuated weight loss due to SGLT2is are not well known. To examine the mechanism of the attenuated weight loss during long-term treatment with an SGLT2i, tofogliflozin, focusing on the antilipolytic effect of insulin on adipose tissue. An integrated analysis was performed using data from two phase 3 studies of 52 weeks of tofogliflozin administration. The antilipolytic effect was evaluated using adipose tissue insulin resistance (Adipo-IR) calculated from the product of the levels of fasting insulin (f-IRI) and fasting free fatty acids (f-FFAs). Data from 774 patients with type 2 diabetes (mean age, 58.5 years; glycosylated hemoglobin, 8.1%; body mass index, 25.6 kg/m2; estimated glomerular filtration rate, 83.9 mL/min/1.73m2; 66% men) were analyzed. Weight loss plateaued between weeks 24 and 52 after decreasing significantly. f-IRI levels decreased significantly from baseline to week 24, and the decrease was maintained until Week 52. f-FFA levels significantly increased, peaked at week 24, then declined from weeks 24 to 52. Adipo-IR levels declined ...Continue Reading

References

Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
May 30, 2012·International Journal of Obesity : Journal of the International Association for the Study of Obesity·L RossmeislováV Štich
Sep 13, 2013·Annals of Internal Medicine·Despoina VasilakouApostolos Tsapas
Jan 28, 2014·The Journal of Clinical Investigation·Aurora MerovciRalph A DeFronzo
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Jun 19, 2015·The Journal of Clinical Endocrinology and Metabolism·Simeon I TaylorKristina I Rother
Jul 17, 2015·Diabetes Care·Giulia FerranniniEle Ferrannini
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 12, 2016·Diabetes Care·Ele FerranniniEric Mayoux
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Aug 27, 2016·Diabetes Care·Giuseppe DanieleMuhammad Abdul-Ghani
Aug 29, 2016·Cardiovascular Diabetology·Antonio CerielloEdoardo Gronda
Jan 28, 2017·Diabetes, Obesity & Metabolism·Hussein Al JoboriMuhammad Abdul-Ghani
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Nov 23, 2017·Diabetes Research and Clinical Practice·Ichiro HorieAtsushi Kawakami
Jan 10, 2018·Diabetes, Obesity & Metabolism·Ren MatsubaYasushi Tanaka
Jan 18, 2018·The Journal of Clinical Endocrinology and Metabolism·Hussein Al JoboriMuhammad Abdul-Ghani
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.